To observe the influence of interferon combined with ribavirin and thymosin alpha - 1 on T lymphocytes subsets in peripheral blood in the treatment of patients with chronic hepatitis C ( CHC ) . Methods 46 patients with CHC were randomly divided into two groups. The treatment group ( 26 cases ) was given thymosin alpha - 1 , with each time 1. 6 mg and twice a week by subcutaneous injection for six months. Besides, the treatment group was also given interferon of 3 million units once every other day by muscle injection as well as ribavirin per os, with each time 0. 4 g, twice a day. The control group was only given interferon combined with thymosin alpha - 1 with the same dosage, usage and course of treatment as the treatment group. The changes of lymphocyte subsets T in peripheral blood among the patients were detected before and after the treatment by using flow cytometry. Results After six months treatment, the CD4 + T cells and CD4 + /CD8 + in treatment group were significantly increased compared with those of the control group ( P < 0. 01 ), while CD8 + T cells were significantly decreased in the treatment group compared with those of the control group ( P<0. 05 ) . Conclusion The combination of interferon, ribavirin and thymosin alpha - 1 have obvious synergy in the treatment of CHC. Disorder of immune function of CD4 + and CD8 + T cells are improved through the therapy of antivirus and immune adjustment.%目的 观察干扰素联合利巴韦林及胸腺肽α1治疗对慢性丙型病毒性肝炎(CHC)患者外周血T淋巴细胞亚群的影响.方法 将46例CHC患者随机分为两组.治疗组26例,应用胸腺肽α1 1.6 mg/次,2次/周,皮下注射,持续6个月;同时肌肉注射干扰素 300万U,隔日1次;口服利巴韦林 0.4 g/次,2次/d.对照组20例,仅用干扰素联合利巴韦林治疗,用量、用法及疗程与治疗组相同.采用流式细胞术检测治疗前后两组患者外周血T淋巴细胞亚群变化.结果 治疗6个月时,治疗组患者CD4+T淋巴细胞及CD4+/CD8+均较对照组显著升高(P＜0.01),而CD8+T淋巴细胞较对照组显著下降(P＜0.05).结论 干扰素联合利巴韦林及胸腺肽α1治疗CHC具有明显的协同作用,随着抗病毒、免疫调节的治疗,CD4+、CD8+T淋巴细胞免疫功能紊乱得到改善.
展开▼
